The synergistic anticancer effect of the bromodomain inhibitor OTX015 and histone deacetylase 6 inhibitor WT-161 in osteosarcoma

BACKGROUND: Osteosarcoma (OS) is a tumour with a high malignancy level and a poor prognosis. First-line chemotherapy for OS has not been improved for many decades. Bromodomain and extraterminal domain (BET) and histone deacetylases (HDACs) regulate histone acetylation in tandem, and BET and HDACs ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Bo, Liu, Lang, Cai, Feng, Peng, Yuanxiang, Tang, Xiaofeng, Zeng, Duo, Li, Teng, Zhang, Feifei, Liang, Yiping, Yuan, Xuhui, Li, Jiayu, Dai, Zhengzai, Liao, Qi, Lv, Xiao-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822767/
https://www.ncbi.nlm.nih.gov/pubmed/35135529
http://dx.doi.org/10.1186/s12935-022-02443-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822767/
https://www.ncbi.nlm.nih.gov/pubmed/35135529
http://dx.doi.org/10.1186/s12935-022-02443-y

Ejemplares similares